Krystal Biotech buy melinda
Start price
21.11.18
/
50%
€18.76
Target price
28.11.18
€21.65
Performance (%)
12.69%
End price
28.11.18
€21.14
Summary
This prediction ended on 28.11.18 with a price of €21.14. The prediction had a final performance of 12.69%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Krystal Biotech | - | - | 92.252% | - |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by melinda for this prediction
In the thread Krystal Biotech diskutieren
SecteurRecherche biotechnologique et médicale Agenda 28/11 | 15:30 Présentation
Operates as a biopharmaceutical company which provides therapies for rare and orphan diseases
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases.
It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments.
The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.
Nombre d'employés : 12 personnes.
(Vom Mitglied beendet)